<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868943</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00056700</org_study_id>
    <secondary_id>NCI-2019-01299</secondary_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU 98418</secondary_id>
    <nct_id>NCT03868943</nct_id>
  </id_info>
  <brief_title>Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma</brief_title>
  <acronym>JAZZ</acronym>
  <official_title>Open Label Safety Study of Solriamfetol to Promote Wakefulness and Improve Cognition and Quality of Life in Patients With Primary Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of solriamfetol in improving sleep in patients&#xD;
      with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol&#xD;
      may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors&#xD;
      (gliomas).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      I. To estimate the safety of solriamfetol at 75 mg daily, 150 mg daily, 300 mg daily as&#xD;
      assessed by NCI CTC Adverse Events (v5.0) in patients with primary gliomas compared to prior&#xD;
      studies.&#xD;
&#xD;
      Secondary Objective(s):&#xD;
&#xD;
      I. To estimate the effect of solriamfetol on sleep by Epworth Sleepiness Scores (ESS) scores&#xD;
      in patients with primary gliomas and compare the effect to previously published scores in&#xD;
      patients with OSA&#xD;
&#xD;
      II. To estimate the effect of solriamfetol on sleep quality by Pittsburgh Sleep Quality Index&#xD;
      scores&#xD;
&#xD;
      III. To estimate the effect of solriamfetol on neurocognitive function based on a&#xD;
      disease-specific neurocognitive battery (see neurocognitive battery below)&#xD;
&#xD;
      IV. To estimate the effect of solriamfetol on patient-reported fatigue (Brief Fatigue&#xD;
      Inventory, Cancer Fatigue Scale) &amp; mood (Beck's Depression Inventory)&#xD;
&#xD;
      V. To estimate the effect of solriamfetol on patient-reported QOL (FACT-Br)&#xD;
&#xD;
      VI. To estimate the effect of solriamfetol on objective sleep-wake times by actigraphy and&#xD;
      sleep diary (pre- vs post-treatment)&#xD;
&#xD;
      Exploratory Objective(s)&#xD;
&#xD;
      I. To explore a biologic gradient effect of increasing doses of solriamfetol on actigraphy&#xD;
&#xD;
      II. To explore differences in clinical activity of solriamfetol by corticosteroid use,&#xD;
      antiepileptic use, and tumor grade.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive solriamfetol orally (PO) once daily (QD) for up to 6 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Adverse Events</measure>
    <time_frame>Approximately 100 days post treatment</time_frame>
    <description>National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be used for scoring toxicity and adverse events. Score of 1 to 5 (1 = mild, 5 = death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Approximately 10 weeks post treatment</time_frame>
    <description>The effect of solriamfetol on patient-reported sleep using Epworth Sleepiness Scale measuring how likely participants are likely to doze off or fall asleep in certain situations, in contrast to feeling tired. Scale of 0 would never doze, 1 - slight chance of dozing, 2 - moderate chance of dozing and 3 - high chance of dozing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Approximately 10 weeks post treatment</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates &quot;poor&quot; from &quot;good&quot; sleep quality by measuring seven areas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month. Score scale 0 - not during the past month, 1 - less than once a week, 2 - once or twice a week and 3 - three or more times a week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Battery Record</measure>
    <time_frame>50-65 minutes at baseline and approximately 70 days post treatment</time_frame>
    <description>Evaluation of attention, concentration, information processing speed, learning/memory and aspects of higher-order executive functions to be done at baseline and end of treatment only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Fatigue Scale (CFS)</measure>
    <time_frame>Baseline, 30 days post treatment and approximately 70 days post treatment</time_frame>
    <description>15-item self-administered patient-reported questionnaire exploring both overall and domain specific fatigue in cancer patients. The instrument explores three fatigue domains: physical effects of fatigue, cognitive effects, and affective issues related to cancer fatigue. To be completed at baseline, fixed dose initiation visit and end of treatment. Score is measured 1 - No, 2 - a little, 3 - somewhat, 4 considerably and 5 - very much.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck's Depression Inventory (BDI)</measure>
    <time_frame>Baseline, 30 days post treatment and approximately 70 days post treatment</time_frame>
    <description>A self-scored questionnaire to assess levels of depression. Score 1-40, with 40 being severe depression and any score over 40 being extreme depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT-Brain module (FACT-Br)</measure>
    <time_frame>Baseline, 30 days post treatment and approximately 70 days post treatment</time_frame>
    <description>An instrument measuring general quality of life (QOL) that reflects symptoms or problems associated with brain malignancies across 5 scales (physical well being, social/family well being, emotional well being, functional well being and additional concerns) Scores 0 - not all all, 1 - a little bit, 2 - somewhat - 3 - quite a bit and 4 - very much. To be completed at baseline, fixed dose initiation visit and end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7 day Actigraphy</measure>
    <time_frame>Approximately over 10 weeks post treatment</time_frame>
    <description>Actigraph devices are worn on the wrist for 7 days and record movements that can be used to estimate sleep patterns using specialized computer software programs. Completion of actigraphy will be done from baseline to end of treatment and recorded with the sleep-diary data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day Patient-Reported Sleep Diary</measure>
    <time_frame>Approximately 10 weeks post treatment</time_frame>
    <description>Participants will be provided a sleep diary at the time of consent and/or study enrollment. All sleep diaries will be collected over 7-days including at pre-study baseline, throughout each dose of the dose escalation phase, and during the first 7-days and last 7-days of the fixed dose drug continuation phase of the study. Caregivers may complete sleep diaries for patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Solriamfetol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Soliramfetol</intervention_name>
    <description>Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).</description>
    <arm_group_label>Solriamfetol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        WHO Grade 2-4 infiltrating glioma by histologic confirmation&#xD;
&#xD;
          -  Where appropriate results from clinically available testing of isocitrate&#xD;
             dehydrogenase (IDH) gene mutation status (for all gliomas), chromosome 1p and 19q&#xD;
             deletion status (for suspected oligodendrogliomas), and MGMT gene promoter methylation&#xD;
             status (for malignant gliomas) must be available in the patient's chart.&#xD;
&#xD;
          -  These studies are standard of care molecular studies that are performed as a part of&#xD;
             routine clinical practice and allow for integrated molecular subtyping of primary&#xD;
             glial tumors.&#xD;
&#xD;
        Epworth Sleepiness Scale (ESS) score &gt;10 within 21 days of enrollment&#xD;
&#xD;
        Clinical and/or radiographic evidence of stable disease within 21 days of enrollment&#xD;
&#xD;
          -  Patients must have completed concurrent chemoradiation with recovery of all&#xD;
             pre-existing toxicity to CTCAE Grade &gt;1&#xD;
&#xD;
          -  Patient who are anticipated to undergo surgery and/or radiation therapy for management&#xD;
             of their tumor during the duration of study treatment are NOT eligible.&#xD;
&#xD;
          -  Patients who are anticipated to undergo adjuvant chemotherapy are eligible as long as&#xD;
             there is no evidence of tumor progression by clinical exam and/or imaging within 21&#xD;
             days of enrollment (see 4.1.2). This determination should be made by clinical&#xD;
             documentation and if there is question discussed with the Study Chair. Adjuvant&#xD;
             chemotherapy is not an exclusion.&#xD;
&#xD;
          -  Patients who are currently undergoing chemotherapy, targeted therapy, immunotherapy,&#xD;
             or salvage treatment and have stable disease by imaging are eligible and can continue&#xD;
             the current anti-cancer therapy. Patients who will require a new anti-cancer treatment&#xD;
             or are anticipated to change anti-cancer treatments are not eligible.&#xD;
&#xD;
        Age &gt; 18 years&#xD;
&#xD;
        Karnofsky performance status â‰¥ 60%&#xD;
&#xD;
        Life expectancy of greater than 4 months&#xD;
&#xD;
        Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
        leukocytes &gt;3,000/mcL absolute neutrophil count &gt;1,500/mcL platelets &gt;100,000/mcL total&#xD;
        bilirubin 1.5 X institutional upper limits of normal AST(SGOT)/ALT(SGPT) &lt;2.5 X&#xD;
        institutional upper limit of normal creatinine within normal institutional limits OR&#xD;
        creatinine clearance &gt;50 mL/min/1.73 m2 for patients with creatinine levels above&#xD;
        institutional normal.&#xD;
&#xD;
          -  The effects of solriamfetol on the developing human fetus are unknown. For this reason&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign an IRB-approved informed consent&#xD;
             document (either directly or via a legally authorized representative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving active radiation therapy (including patients who are within 28 days of&#xD;
             completing radiation therapy)&#xD;
&#xD;
          -  Anticipated to undergo radiation therapy or require neurosurgical intervention during&#xD;
             the period of active treatment(i.e. within the next 4 months)&#xD;
&#xD;
          -  Contraindication to solriamfetol based on drug-drug interactions or concurrent&#xD;
             systemic illness that precludes drug treatment&#xD;
&#xD;
          -  Patients who have not recovered to &lt; CTCAE grade 2 toxicities related to prior or&#xD;
             current therapy are ineligible.&#xD;
&#xD;
          -  Exception for laboratory-based or other adverse event that is stable and not&#xD;
             anticipated to interfere with study related treatment must be reviewed and approved by&#xD;
             the study chair&#xD;
&#xD;
          -  Customary bedtime later than midnight&#xD;
&#xD;
          -  Known and/or documented history of obstructive sleep apnea (OSA)&#xD;
&#xD;
          -  Uncontrolled behavioral or psychiatric disorder (including suicidal ideation)&#xD;
&#xD;
          -  Current excessive caffeine use (&gt; 600 mg/day or &gt; 6 cups of coffee/day)&#xD;
&#xD;
          -  Current or prior history of alcohol or drug abuse within the last 2 years as assessed&#xD;
             by the treating clinician&#xD;
&#xD;
          -  Nicotine dependence that is currently interfering with sleep based on assessment by&#xD;
             the treating clinician&#xD;
&#xD;
          -  Concurrent use of selective serotonin or norepinephrine reuptake inhibitors (e.g.&#xD;
             selective serotonin reuptake inhibitor [SSRI], serotonin and norepinephrine reuptake&#xD;
             inhibitors [SNRI]) within 14 days of study enrollment&#xD;
&#xD;
          -  Patients who are currently taking these agents may be tapered at the direction of the&#xD;
             treating physician prior to study enrollment&#xD;
&#xD;
          -  Patients taking other medications such as narcotics, benzodiazepines, antipsychotics,&#xD;
             antiepileptics, corticosteroids, or over-the-counter sleep aids can be enrolled. It is&#xD;
             recommended that the doses of these medications remain the same throughout the portion&#xD;
             of active study treatment unless there is a medical indication for dose adjustment&#xD;
             which will be determined by the treating physician&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to solriamfetol&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because there is an unknown but potential&#xD;
             risk for adverse events in nursing infants secondary to treatment of the mother with&#xD;
             solriamfetol, breastfeeding should be discontinued if the mother is treated with&#xD;
             solriamfetol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Strowd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Fansler, RN</last_name>
    <phone>336-713-3539</phone>
    <email>arcarrol@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest Baptist Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roy Strowd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

